ArticleVirology journal2025
Modulation of transferrin receptor by HIV-2.
Article in Virology journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundHuman immunodeficiency viruses (HIV-1 and HIV-2), are the causative agents of the acquired immunodeficiency syndrome (AIDS), that share substantial genomic and structural similarities, yet differ in replication dynamics and disease progression. While HIV-1 primarily enters host cells via CD4 and the chemokine co-receptors CCR5 and CXCR4, HIV-2 engages a broader range of chemokine receptors. The transferrin receptor (TFRC/CD71), a membrane protein essential for iron uptake and immune function, has recently been implicated in viral entry by other pathogens. In this study, we investigated the modulation of TFRC expression following transduction with HIV-1 and HIV-2 pseudovirions.
methodsHuman embryonic kidney (HEK-293T), immortalized T lymphocyte (Jurkat), and monocytic (THP-1) cells were transduced with pseudotyped HIV-1 and HIV-2 virions. Quantitative PCR (qPCR) and western blotting were employed to assess changes in TFRC expression at the mRNA and protein levels, respectively. To elucidate the underlying mechanism, we examined the role of the HIV-2 regulatory protein Tat in TFRC modulation. Additionally, we assessed whether TFRC upregulation correlates with increased iron uptake during the early phase of infection.
resultsWe observed a significant upregulation of TFRC mRNA and protein levels in HEK-293T cells 27 h post-transduction with HIV-2, but not with HIV-1. In Jurkat T cells, TFRC transcript levels were significantly increased at 36 and 40 h following HIV-2 transduction. At the proteomic level, TFRC abundance was modestly reduced in HIV-2-transduced cells at 36 and 48 h, suggesting a potential compensatory cellular response. In THP-1 cells, HIV-2 induced a significant downregulation of TFRC at both the transcriptomic and proteomic levels at 36 h. Mechanistic studies demonstrated that this modulation is likely dependent on a functional HIV-2 Tat protein. Furthermore, HIV-2 transduction led to elevated intracellular iron levels in Jurkat cells at 48 h post-transduction.
conclusionThese findings identify TFRC as a novel, Tat-dependent host target of HIV-2, providing new insights into the virus's broader receptor usage and its potential influence on host iron metabolism and viral tropism.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.